Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase...
- Mechanism
- Curator reviewed · 1 reference
Abexinostat is a novel histone deacetylase (HDAC) inhibitor. HDAC inhibitors target HDAC enzymes and inhibit the proliferation of cancer cells and induce cancer cell death, or apoptosis. Histone deacetylation is carried out by a family of related HDAC enzymes. Inhibition of these enzymes causes changes to chromatin structure and to gene expression patterns, which results in the inhibition of proliferation of cancer cells, and induction of apoptosis.
- Formula / weight
- C21H23N3O5 · 397.431 g/mol (avg)
- Code names
- CRA-024781 · CRA 24781 · PCI-24781 · PZP-115891
Resolves to
MAUCONCHVWBMHK-UHFFFAOYSA-NSMILESCN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC1=CC=C(C=C1)C(=O)NOWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Abexinostat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account